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There is insufficient data about the role of eradication of H. pylori after endoscopic resection
(ER) for gastric dysplasia. The aim was to investigate the benefit of H. pylori eradication
after ER in patients with gastric dysplasia to prevent metachronous gastric neoplasms.
Materials and Methods
We retrospectively reviewed 1872 patients who underwent ER of gastric dysplasia. We
excluded patients with a follow-up period of <2 years or who had not undergone tests for
active H. pylori infection. A total of 282 patients were enrolled. The patients were catego-
rized into those without active H. pylori infection (H. pylori-negative group, n = 124), those
who successfully underwent H. pylori eradication (eradicated group, n = 122), and those
who failed or did not undergo H. pylori eradication (persistent group, n = 36).
Results
Metachronous recurrence was diagnosed in 36 patients, including 19 in the H. pylori-nega-
tive group, 10 in the eradicated group, and 7 in the persistent group. The cumulative inci-
dence of metachronous recurrence was significantly lower in the H. pylori-eradicated group
in comparison with either of the H. pylori-persistent (non-eradicated or failed) groups (p =
0.039). Similarly, the incidence of metachronous recurrence was significantly lower in the
H. pylori-eradicated group compared with the H. pylori-negative group (p = 0.041).
Conclusion
Successful H. pylori eradication may reduce the development of metachronous gastric neo-
plasms after ER in patients with gastric dysplasia.
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Introduction
Helicobacter pylori (H. pylori) infection is a group I carcinogen for gastric cancer as defined by
the International Agency for Research on Cancer (IARC), a subdivision of the World Health
Organization (WHO) [1]. Correa et al. contend that H. pylori infection is closely associated
with progression to gastric atrophy, intestinal metaplasia (IM), dysplasia, and cancer [2]. The
reported progression rate of atrophic gastritis, intestinal metaplasia and dysplasia to gastric
cancer varies from 0 to 1.8%, 0 to 10%, and 0 to 73% per year, respectively [3]. Male gender is
the significant risk factor for the development of gastric cancer, with a nearly 2:1 male to female
dominance [4]. Previous studies showed that seroprevalence of H. pylori was higher in males
than in females [5–7]. Currently, endoscopic resection (ER) is the accepted standard treatment
for selected cases of early gastric cancer (EGC) in Korea. Because gastric dysplasia is a precan-
cerous lesion, this pathology also can be a candidate for ER, which has the additional benefit of
providing a histologic diagnosis that could result in an upgrade from biopsy-proven dysplasia
to cancer [8]. In Korea, ER is widely used for the treatment of gastric dysplasia and EGC [9].
ER can preserve the stomach; however, metachronous gastric cancer may develop in the stom-
ach remnant after the procedure [10,11]. For this reason, endoscopic surveillance for meta-
chronous gastric neoplasms has become an emerging issue during the follow-up interval after
ER. Some studies have shown that the eradication of H. pylori after ER is helpful to prevent the
development of metachronous gastric cancer [12–14]; however, several other studies have
failed to show a prophylactic benefit for H. pylori eradication [15,16]. At present, the guidelines
for the treatmentH. pylori infection in Korea recommends eradication of H. pylori after ER of
EGC according to the findings of positive studies [17]. However, there is insufficient data
about the role of eradication ofH. pylori after ER for the treatment of gastric dysplasia. The
aim of this study was to determine whether H. pylori eradication prevents the development of
metachronous gastric neoplasms in patients with gastric dysplasia following ER.
Methods
Patients
Between January 2007 and January 2014, 1872 patients were diagnosed with low- and high-
grade gastric dysplasia and underwent ER at Severance Hospital, Seoul, Korea. Of these
patients, we excluded 612 patients who did not undergo tests for active H. pylori infection
including a urea breath test, a rapid urease test, or histopathological examination. We also
excluded 971 patients with only a short-term follow-up period (<2 years) and 7 patients who
had a recurrence in a previous ER site. Ultimately we enrolled a total of 282 patients for analy-
sis in this study. The ER procedures were performed by expert endoscopists who had a previ-
ous experience of over 1000 gastric endoscopy cases per year. The patients were divided into
three groups according to presence of active H. pylori infection and successful eradication. The
patient selection and grouping flow diagram is shown in Fig 1: (1) those without active H.
pylori infection at the time of ER (the H. pylori-negative group, n = 124), (2) those with a suc-
cessfully treated H. pylori infection (the H. pylori-eradicated group, n = 122), (3) those who
failed treatment ofH. pylori infection or were untreated (the H. pylori-persistent group,
n = 36). A time interval of at least 6 months was observed between H. pylori treatment and the
development of metachronous gastric neoplasms to accurately assess the effect of H. pylori
eradication on the incidence of metachronous gastric lesions after ER. Patients were evaluated
in terms of their clinicopathological characteristics including age, gender, tumor location, gross
appearance, histological type, tumor size, multiplicity of tumors, and the presence of co-mor-
bid ulcers such as gastric ulcer or duodenal ulcer. The definition of smoking and alcohol
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drinking history were divided into yes or no. The clinicopathological characteristics were ana-
lyzed retrospectively from patient medical records. The Institutional Review Board (IRB) of
Severance Hospital approved this study. We received a consent exemption from the IRB.
Patients records and information was anonymized.
Evaluation of H. pylori infection status and treatment
To determine theH. pylori infection status rapid urease and urea breath tests and histological
assessment were used. Patients who showed negative results for all three examinations were
assigned to the H. pylori-negative group. The patients who had a positive result for at least one
test among these were assigned to the active H. pylori infection group. The active H. pylori
infection group was subdivided into two groups depending on their infection treatment out-
come and assigned to either the eradicated or persistent groups. H. pylori eradication therapy
was carried out in accordance with the guideline for treatment of H. pylori infection in Korea
[17]. Of the total 282 patients, 122 patients assigned to the eradicated group received triple
therapy of a standard dose of a proton pump inhibitor (PPI), 500 mg of clarithromycin, and
1000 mg of amoxicillin twice a day for 7 days. Twelve patients in the eradicated group who ini-
tially failed eradication after conventional triple therapy underwent a secondary regimen of bis-
muth-based quadruple therapy.
Follow-up schedule after the endoscopic resection
Follow-up endoscopic examinations with endoscopy and biopsy were conducted at regular
intervals after endoscopic resection (3 and 12 months and annually after the first year of
Fig 1. A flow chart of patient enrollment.
doi:10.1371/journal.pone.0143257.g001
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follow-up). A biopsy was performed at the previous ER site and any other sites suspected to
represent a recurrence of metachronous neoplasm.
Histopathological evaluation of the gastric lesion
Biopsy or resection specimens were examined by two expert pathologists. The histology of gas-
tric cancers were reviewed according to the new Japanese classification for gastric carcinomas
[18] and the grade of gastric dysplasia was categorized according to the Vienna classification
[19]. A metachronous neoplasm was defined as evident dysplasia or carcinoma that developed
subsequently (i.e., more than 6 months after ER of the primary gastric dysplasia).
Statistical analysis
The chi-square test and Fisher’s exact test were used to compare the clinicopathological factors
between the groups according to the presence/absence of active H. pylori infection and failed/
successful eradication. The Student’s t-test was used for non-categorical variables in the inter-
group comparisons of clinicopathological characteristics. The threshold for statistical signifi-
cance was set at p< 0.05. The incidence of metachronous gastric neoplasms was calculated by
the Kaplan-Meier method, and compared among the three groups by the log-rank test. A Cox
proportional hazards model and multivariate analyses were used for risk assessment. Statistical
analyses were performed using the Statistical Package for Social Sciences Version 18.0 (SPSS
Inc., Chicago, IL, USA).
Results
Baseline characteristics of the study population
The baseline characteristics of the three groups are summarized in Table 1. The enrolled
patients included 200 (70.9%) males and 82 (29.1%) females and the median age was 68 years
old. There were no significant differences among the three groups in the sex ratio, smoking and
alcohol history, previous ulcer history and histology, or the location and size of the tumor. The
clinicopathological characteristics of patients according to the development of metachronous
neoplasms are shown in Table 2. Among the 282 patients, metachronous recurrence developed
in 36 (14.6%) patients after ER of gastric dysplasia. There were no significant differences
between the two groups in the sex ratio, smoking and alcohol consumption history, initial his-
tology, lesion size, or location of the tumor. The metachronous group was significantly older
than the non-metachronous group (p = 0.035).
Metachronous recurrence
During the follow-up period, 36 metachronous recurrences were found on endoscopy and con-
firmed by biopsy. Metachronous recurrence was diagnosed in 19 of 124 patients (15.3%) in the
H. pylori-negative group, in 10 of 122 patients (8.2%) in the eradicated group, and in 7 of 36
patients (19.4%) in the persistent group. The median time until metachronous recurrence was
36 months (range, 6–85 months). The cumulative incidence of metachronous recurrence was
significantly lower in theH. pylori-eradicated group in comparison with either of theH. pylori-
persistent (non-eradicated or failed) groups (p = 0.039, Fig 2A). Moreover, this result was dis-
tinct by 36 months after ER. Similarly, the incidence of metachronous recurrence was signifi-
cantly lower in theH. pylori-eradicated group compared with the H. pylori-negative group
(p = 0.041, Fig 2B). Univariate analysis using Cox’s proportional hazards model showed that
the persistent group had a higher risk of developing metachronous gastric neoplasms than the
eradicated group (hazard ratio [HR] 3.974, p = 0.005).
Helicobacter pylori and Metachronous Neoplasms
PLOSONE | DOI:10.1371/journal.pone.0143257 November 18, 2015 4 / 9
Discussion
According to the current Korean guidelines for treatment ofH. pylori infection, eradication
therapy is recommended after ER of EGC. H. pylori infection plays an important role in the
development of gastric cancer. Huang et al. show by a meta-analysis that the odds ratio for the
development of gastric cancer inH. pylori-infected patients is 1.92, and younger patients with
H. pylori infection have a higher relative risk to develop gastric cancer than older patients [20].
Therefore, there is some evidence thatH. pylori eradication could prevent metachronous recur-
rence after ER of EGC; however, data are still lacking whether there are prophylactic benefits of
H. pylori eradication to prevent the development of metachronous lesions after ER of pre-
malignant lesions such as gastric dysplasia.
Rapid urease test, histology, and urea breath tests are the recommended diagnostic tests for
H. pylori infection. The urea breath test had high sensitivity and specificity ( 95%). However,
false negative rates greater than 30% have been reported when antibiotics or PPI were used. For
the rapid urease test, test sensitivity ranges from 85–98% and specificity ranges from 89–100%.
Hematoxylin and eosin staining has a sensitivity of 69–93% and a specificity of 87–90% [17].
Table 1. Baseline characteristics of enrolled patients.
Characteristic H. pylori negative group (n = 124,
%)
Eradicated group (n = 122,
%)




Mean age (year) a 68.89 ± 8.78 66.64 ± 8.55 67.61 ± 8.49 0.126
Sex 0.621
Male 91 (73.4) 83 (68.0) 26 (72.2)
Female 33 (26.6) 39 (32.0) 10 (27.8)
Smoking 47 (37.9) 62 (50.8) 14 (38.9) 0.347
Alcohol 58 (46.8) 62 (50.8) 20 (55.6) 0.324
Family history of Gastric cancer 19 (15.3) 26 (21.3) 6 (16.7) 0.462
Previous ulcer 5 (4.0) 1 (0.8) 2 (5.6) 0.793
Histology 0.597
Low-grade dysplasia 85 (68.8) 87 (71.3) 26 (72.2)
High-grade dysplasia 39 (31.5) 35 (28.7) 10 (27.8)
Location 0.418
Upper 1/3 11 (8.9) 13 (10.7) 1 (2.8)
Middle 1/3 53 (42.7) 40 (32.8) 17 (47.2)
Lower 1/3 60 (48.4) 69 (56.6) 18 (50.0)
Gross appearance 0.504
Elevated 117 (94.4) 106 (86.9) 20 (55.6)
Flat 4 (3.2) 13 (10.7) 1 (2.8)
Depressed 3 (2.4) 3 (2.5) 1 (2.8)
Multiplicity 14 (11.3) 12 (9.8) 1 (2.8) 0.178
Maximum diameter of lesion (mm)a 10.84 ± 7.56 11.08 ± 8.87 10.55 ± 6.22 0.960
Metachronous recurrenceb 19 (15.3) 10 (8.2) 7 (19.4) 0.095
Dysplasia 15 (79.0) 6 (60.0) 4 (57.2)
Cancer 4 (21.0) 4 (40.0) 3 (42.9)
Follow up duration (months, median,
range)
53.0 (26.3–85.7) 58.3 (24.3–85.9) 57.2 (28.1–85.2) 0.026
Values are presented as mean ± SD or n (%). H. pylori, Helicobacter pylori.
aStatistical signiﬁcance were tested by oneway analysis of variances among groups
bStatistical signiﬁcance were tested by Fisher’s exact test between three groups.
doi:10.1371/journal.pone.0143257.t001
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Table 2. Comparison of clinicopathologic characteristics between patients with and without metachronous recurrence.
Characteristics Non-metachronous group (n = 246, %) Metachronous group (n = 36) P-value
Mean age (year) 67.35 ± 8.72 70.47 ± 7.93 0.035
Sex (male) 174 (70.7) 26 (72.2) 0.854
Smoking 108 (43.9) 15 (41.7) 0.801
Alcohol 120 (48.8) 20 (55.6) 0.448
Previous ulcer 6 (2.4) 2 (5.6) 0.271
Histology 0.778
Low-grade dysplasia 172 (69.9) 26 (72.2)
High-grade dysplasia 74 (30.1) 10 (27.8)
Location 0.137
Upper 1/3 25 (10.2) 0 (0)
Middle 1/3 95 (38.6) 15 (41.7)
Lower 1/3 126 (51.2) 21 (58.3)
Gross appearance 0.618
Elevated 223 (90.7) 34 (94.4)
Flat 17 (6.9) 1 (2.8)
Depressed 6 (2.4) 1 (2.8)
Multiplicity 26 (10.6) 1 (2.8) 0.222
Maximum diameter of lesion (mm) 11.15 ± 8.08 9.17 ± 6.78 0.212
Values are presented as mean ± SD or n (%). H. pylori, Helicobacter pylori.
doi:10.1371/journal.pone.0143257.t002
Fig 2. (A) The cumulative incidence of metachronous recurrence was significantly lower in theH. pylori-eradicated group in comparison with the H. pylori-
persistent (non-eradicated or failed) groups (p = 0.039). (B) The cumulative incidence of metachronous recurrence was significantly lower in theH. pylori-
eradicated group in comparison with theH. pylori negative group (p = 0.041).
doi:10.1371/journal.pone.0143257.g002
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Recently, ER of gastric dysplasia has become accepted as a reasonable treatment option.
Although the ER of low-grade dysplasia diagnosed by forceps biopsy is controversial, tumors
with a size>1 cm and/or with surface redness or nodularity are believed to have significant
risk for high-grade dysplasia or EGC [21]. Therefore, in Korea, ER is commonly performed for
patients with both low- and high-grade dysplasia.
Since a risk of metachronous recurrence still exists in the remnant stomach following ER of
gastric dysplasia, surveillance for metachronous gastric neoplasms is believed important during
the follow-up period. Gutierrez-Gonzalez et al. show that identical genetic alterations are pres-
ent in dysplasia and the surrounding intestinal metaplasia (IM) [22]. They also demonstrate
that genetic changes in the IM are likely to lead to dysplasia, and further genetic alterations can
cause the progression of dysplasia to gastric cancer referred to as “cancer in adenoma” [22,23].
Several causative genetic and epigenetic changes in the IM or dysplasia are reversed byH. pylori
eradication. In this study, successful eradication of H. pylori infection significantly lowers
metachronous recurrence; therefore, the eradication ofH. pylori infection may prevent the
emergence of metachronous gastric neoplasms after ER of gastric dysplasia.
There are some reports thatH. pylori eradication has a prophylactic effect to prevent meta-
chronous gastric neoplasms after ER of EGC. One large, randomized controlled trial shows a
reduced incidence of metachronous gastric cancer (odds ratio [OR] 0.353, 95% confidence
interval [CI] 0.161–0.775, p = 0.009), and recommends that prophylactic eradication should be
performed after ER [12]. However, this trial doesn’t address whether there is a similar benefit
to eradicate H. pylori infection after ER of gastric dysplasia. Unlike previous studies, we focused
the role of H. pylori eradication in the development of metachronous lesions after ER of gastric
dysplasia which was a precancerous lesion. And, in our study, H. pylori eradication could also
prevent metachronous lesions after ER of gastric dysplasia, similar EGC.
H. pylori infection both initiates and promotes the gastric carcinogenesis; therefore, eradica-
tion should both inhibit newly developed gastric cancers and reduce the growth rate of existing
gastric cancers [24]. After a median follow-up period of 36 months, metachronous recurrence
developed in 36 patients. Although a 3-year follow-up period is short, eradication of H. pylori
after ER of dysplasia might inhibit the occurrence of new gastric neoplasms and delay the
growth rate of gastric cancer. Our study has some limitations. TheH. pylori-negative group
showed a lower metachronous recurrence rate than non-eradicated group, but a higher recur-
rence rate than the eradicated group. This unexpected result may be due to false negativeH.
pylori infection status. Additional potential causes for the false negative result might be due to
antibiotic therapy administered to treat other infections, the masking effect of proton pump
inhibitors (PPIs), inadequate sampling, or suboptimal staining technique [25]. We didn’t ana-
lyze the background mucosa for atrophy and intestinal metaplasia, which might also affect the
rate of metachronous recurrence in the H. pylori-negative group. We didn’t consider the re-
infection of H. pylori. However, five (4.1%) patients were re-infected withH. pylori in eradi-
cated group. Therefore, the annual re-infection rate was quite low.
In conclusion, this study demonstrates thatH. pylori eradication after ER in patients with
gastric dysplasia may reduce the development of subsequent metachronous gastric neoplasms.
Therefore, H. pylori eradication is recommended after ER of gastric dysplasia.
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